scholarly article | Q13442814 |
P356 | DOI | 10.1007/S11739-017-1628-6 |
P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s11739-017-1628-6 |
P698 | PubMed publication ID | 28191610 |
P50 | author | Francesco Violi | Q37834358 |
Domenico Prisco | Q43281338 | ||
Anna Falanga | Q54574948 | ||
Walter Ageno | Q56563198 | ||
Pasquale Pignatelli | Q57057602 | ||
Mauro Silingardi | Q57076751 | ||
Giovanni Davi | Q64541371 | ||
Francesco Dentali | Q88396220 | ||
Gualtiero Palareti | Q91131655 | ||
P2093 | author name string | Armando D'Angelo | |
Francesca Santilli | |||
Raimondo De Cristofaro | |||
Antonella Tufano | |||
Giovanni Di Minno | |||
Cecilia Becattini | |||
Gualberto Gussoni | |||
Luca Masotti | |||
Roberto M Santi | |||
FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) | |||
SIMI (Italian Society of Internal Medicine) | |||
SISET (Italian Society for the Study of Haemostasis and Thrombosis) | |||
P2860 | cites work | Peri-procedural management of patients taking oral anticoagulants | Q26801859 |
Direct oral anticoagulants: efficacy and safety in patient subgroups | Q27023677 | ||
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events | Q28080616 | ||
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects | Q28247385 | ||
Idarucizumab for Dabigatran Reversal | Q28263802 | ||
Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review | Q33468803 | ||
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co | Q34093427 | ||
Apixaban with antiplatelet therapy after acute coronary syndrome | Q34202772 | ||
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society | Q34412804 | ||
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report | Q34513594 | ||
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers | Q34615829 | ||
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation | Q34651051 | ||
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures | Q34683960 | ||
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis | Q35187005 | ||
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review | Q35559027 | ||
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752584 | ||
Chronic kidney disease: the global challenge | Q36017142 | ||
New oral anticoagulants and the cancer patient. | Q37519054 | ||
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. | Q37552621 | ||
How I treat anticoagulated patients undergoing an elective procedure or surgery | Q38038988 | ||
The promise of novel direct oral anticoagulants | Q38041803 | ||
The laboratory and the direct oral anticoagulants | Q38097025 | ||
Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly | Q38124014 | ||
Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. | Q38129707 | ||
New oral anticoagulants in practice: pharmacological and practical considerations | Q38180988 | ||
Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? | Q38219531 | ||
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. | Q38221642 | ||
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials | Q38223081 | ||
Stroke prevention in patients with atrial fibrillation and renal dysfunction | Q38223517 | ||
Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis | Q38248341 | ||
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate | Q38420791 | ||
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial | Q38469560 | ||
Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal | Q38543288 | ||
Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials. | Q38719983 | ||
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. | Q38748850 | ||
Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent | Q39220291 | ||
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors | Q41501792 | ||
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. | Q41968675 | ||
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards | Q42791455 | ||
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry | Q45841050 | ||
Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study | Q45860268 | ||
Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI. | Q45879103 | ||
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q45884499 | ||
Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry | Q46719193 | ||
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism | Q46848170 | ||
Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. | Q50934656 | ||
Rivaroxaban induced liver injury: A cholestatic pattern. | Q52983227 | ||
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. | Q53038051 | ||
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. | Q53166156 | ||
Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? | Q54736318 | ||
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation | Q57626444 | ||
Decision making for oral anticoagulants in atrial fibrillation: The ATA-AF study | Q57628694 | ||
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism | Q74197149 | ||
Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism | Q77499876 | ||
6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII | Q79642715 | ||
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay | Q82070566 | ||
The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S | Q83275741 | ||
In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban | Q83942064 | ||
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor | Q83943517 | ||
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux | Q84039953 | ||
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome | Q84968518 | ||
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) | Q84985096 | ||
Use of PER977 to reverse the anticoagulant effect of edoxaban | Q85912324 | ||
Real-world variability in dabigatran levels in patients with atrial fibrillation: reply | Q86953377 | ||
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels | Q87055126 | ||
The perioperative management of new direct oral anticoagulants: a question without answers | Q87082444 | ||
Perioperative Management of Dabigatran: A Prospective Cohort Study | Q87294444 | ||
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers | Q87842081 | ||
New oral anticoagulants in patients with atrial fibrillation - Authors'reply | Q88225137 | ||
P433 | issue | 3 | |
P921 | main subject | internal medicine | Q11180 |
P304 | page(s) | 387-406 | |
P577 | publication date | 2017-02-13 | |
P1433 | published in | Internal and emergency medicine | Q26842320 |
P1476 | title | Italian intersociety consensus on DOAC use in internal medicine. | |
P478 | volume | 12 |
Q88764009 | Cardiac tamponade due to apixaban therapy in patient with unknown pericardial hemangioma |
Q50002162 | Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. |
Q90364741 | Determinants of health-related quality of life: a cross-sectional investigation in physician-managed anticoagulated patients using vitamin K antagonists |
Q90140495 | Direct oral anticoagulants in factor VII deficiency patient |
Q52676289 | Direct oral anticoagulants: what can we learn? |
Q88564872 | Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective |
Q48299993 | ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations |
Q63242297 | Estimating renal function in patients with atrial fibrillation: which dose of direct oral anticoagulants? |
Q38635568 | Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon? |
Q52665386 | Intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: significant differences between direct oral anticoagulants and vitamin K antagonists. |
Q48627362 | Is it reasonable to use a lower DOAC dose in some patients with VTE? NO. |
Q36413874 | Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes. |
Q56381361 | Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry |
Q51742474 | Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban. |
Q89338753 | NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study |
Q57056338 | Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer |
Q91978190 | Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients |
Q50001981 | The involvement of pharmacies in the screening of undiagnosed atrial fibrillation. |
Q56384852 | The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures |
Search more.